Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...
Johnson & Johnson has launched the TECNIS PureSee™ intraocular lens in India, catering to individuals with presbyopia. The ...
A class action lawsuit launched in Auckland today questioning Johnson and Johnson cold and flu products follows similar suits ...
Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...
We recently published a list of 17 Best Stocks for Kids According to Jim Cramer. In this article, we are going to take a look ...
The lawsuit says Kiwis have been deceived for about two decades about an ingredient in cold and flu medicine.